Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Europe’s CHMP Okays Samsung’s Infliximab Biosimilar

This article was originally published in PharmAsia News

Executive Summary

Samsung Bioepis' infliximab biosimilar, Flixabi, has won a green light from the European Medicines Agency's CHMP for a broad range of indications, marking another step forward for the South Korean firm’s international ambitions.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register